NovoCure Ltd (NVCR)
NASDAQ:NVCR
Want to see NVCR full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.36Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and clinical outlook anchored by a strong start to 2026: double-digit revenue growth (12% YoY), rapid Optune Pax FDA approval and early U.S. launch traction, encouraging PANOVA-4 data, gross margin improvement, and tightened adjusted EBITDA versus prior year. These positives are tempered by a sizable one-time GAAP share‑based compensation charge that materially widened GAAP net loss and drove a large G&A increase, modest near-term revenue contribution from new indications, remaining reimbursement timing uncertainty, and ongoing trial strategy work for LUNAR-2. On balance, the company demonstrated substantive commercial momentum and multiple upcoming catalysts that outweigh the near-term accounting-driven losses and operational uncertainties.Company Guidance
Net Revenue Growth
Net revenue of $174 million in Q1 2026, up 12% year-over-year; company raised full-year revenue guidance to $690M–$710M (5%–8% growth), citing strong Q1 momentum.
Active Patient Growth
Global active patients grew 9% year-over-year; strong regional active patient growth in Japan (+20%), Germany (+12%), France (+9%) and a 17% increase in the global market segment driven by Spain.
Optune Pax FDA Approval and U.S. Launch
FDA approval on February 11, 2026 and rapid commercialization: 868 healthcare providers certified shortly after approval, 169 prescriptions received, 90 patient starts completed, 83 patients on therapy at quarter end, and a reported backlog of starts in the funnel.
Early Commercial Reimbursement Win
First major U.S. payer coverage for Optune Pax secured with Elevance Health, covering over 30 million lives; company notes existing contracts with most U.S. payers (coverage policy is primary gating factor).
Positive PANOVA-4 Topline Data in Metastatic Pancreatic Cancer
PANOVA-4 met its primary endpoint: disease control rate 74% vs historical control 48%; median duration of therapy 25.6 weeks, supporting feasibility of TTFields in the metastatic setting.
Product and Patient Experience Improvements
Launched several product enhancements (HCP portal, lighter HFE arrays for Optune Gio, mobile app); 90-day persistence improved from below 70% (2024) to ~73% in 2025; new torso array design progressing with usability testing completed and planned availability for trials by year-end.
Optune Lua Commercial and Revenue Progress
Optune Lua net revenue $3 million in Q1 2026 vs $1.5 million in Q1 2025; national reimbursement in Japan received in March with commercial patient treatments initiated.
Gross Margin and Adjusted EBITDA Improvement
Gross margin improved to 78% in Q1 2026 from 75% in Q1 2025 (driven by lower array costs and supplier price improvements); adjusted EBITDA improved to negative $0.3M from negative $5M year-over-year; full-year adjusted EBITDA guidance updated to negative $15M to breakeven.
Clinical and Strategic Catalysts
TRIDENT Phase III top-line data expected in Q2 (evaluating earlier use of Optune Gio with chemoradiation); ongoing large trials including KEYNOTE D58 (700+ patients) expected to fully enroll by year-end; active exploration of combining TTFields with RAS inhibitors given promising preclinical synergy.
Balance Sheet Position
Cash and investments of $432 million as of March 31, 2026, providing runway to support launches and clinical programs.
NVCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $11.93 | $15.21 | +27.49% |
Feb 26, 2026 | $14.99 | $13.75 | -8.27% |
Oct 30, 2025 | $13.48 | $12.82 | -4.90% |
Jul 24, 2025 | $16.51 | $12.54 | -24.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NovoCure Ltd (NVCR) report earnings?
NovoCure Ltd (NVCR) is schdueled to report earning on Jul 23, 2026, TBA (Confirmed).
What is NovoCure Ltd (NVCR) earnings time?
NovoCure Ltd (NVCR) earnings time is at Jul 23, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVCR EPS forecast?
NVCR EPS forecast for the fiscal quarter 2026 (Q2) is -0.33.